Open an account

Rein Therapeutics

RNTX · NASDAQ

$0.5951+$0.0431 (+7.81%)TodayMarket closed ·
Prev close $0.552

About RNTX

Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. The company is headquartered in Austin, Texas and currently employs 10 full-time employees. The company went IPO on 2017-06-29. The firm's lead product candidate, LTI-03 (idiopathic pulmonary fibrosis), is a novel, synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. Its second product candidate, LTI-01, is a proenzyme that has completed Phase 1b and Phase 2a clinical trials for the treatment of loculated pleural effusions. LTI-01 has received Orphan Drug Designation in the United States and European Union and Fast Track Designation in the United States. Its pipeline also includes LTI-05 (cystic fibrosis).

Employees
10
Headquarters
Austin, Texas
Listed
Jun 29, 2017
Sector
Health Care
Industry
Biotechnology
Website
reintx.com

RNTX key statistics

Market cap
51.34M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
445.43K
Volume
296.44K
Open price
$0.545
High today
$0.6072
Low today
$0.5432
52 Week high
$2.18
52 Week low
$0.5401

Rein Therapeutics (RNTX) at a glance

As of Oct 20, 2026, Rein Therapeutics (RNTX) shares are priced at $0.5951, giving the company a market cap of 51.34M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.5432 and $0.6072. The current price is 9.6% above the day's low and 2.0% below its high.

Volume so far is 296.44K shares, below the average of 445.43K shares a day.

Over the past year Rein Therapeutics has ranged from $0.5401 to $2.18, and now sits 3% of the way up that range.

Rein Therapeutics met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported -$0.10 per share against an estimate of -$0.1734.

The average analyst price target is $6.12, 928.4% above the current price, from 3 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

67%of 3 analyst ratings say Buy
  • Buy66.7%
  • Hold33.3%
  • Sell0.0%
Price target · 4 analystsAvg $6.12
Low
$4.04
Now
$0.5951
High
$8.40

RNTX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 38.5% on average.

  1. Q3 FY24: reported -$0.27 per share against an estimate of -$0.4182
  2. Q4 FY24: reported -$2.20 per share against an estimate of -$0.1418
  3. Q1 FY25: reported -$0.25 per share against an estimate of -$0.2499
  4. Q2 FY25: reported -$0.28 per share against an estimate of -$0.2244
  5. Q3 FY25: reported -$0.21 per share against an estimate of -$0.2448
  6. Q4 FY25: reported -$1.09 per share against an estimate of -$0.2193
  7. Q1 FY26: reported -$0.19 per share against an estimate of -$0.4998
  8. Q2 FY26: reported -$0.10 per share against an estimate of -$0.1734

RNTX news

  • 12 Health Care Stocks Moving In Friday's Pre-Market Session

  • 12 Health Care Stocks Moving In Monday's Intraday Session

  • Press releasePRNewswire

    XtalPi and DoveTree Announce Landmark $6 Billion AI Drug Discovery Collaboration

  • Press releasePRNewswire

    Rein Therapeutics Announces Adjournment of Annual Meeting of Stockholders

  • 12 Health Care Stocks Moving In Thursday's After-Market Session

  • Rein Therapeutics Doses First Patient in Phase 2 Trial for IPF Drug LTI-03

  • Press releasePRNewswire

    Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF

  • Press releasePRNewswire

    Rein Therapeutics Presents Two Posters at the American Thoracic Society 2025 International Conference

Similar companies

Companies in the same industry as Rein Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.